The ENCHANTMENT HIV Study

Last updated: March 9, 2026
Sponsor: Massachusetts General Hospital
Overall Status: Completed

Phase

2

Condition

Heart Failure

Hyponatremia

Hiv Infections

Treatment

Placebo oral tablet

Sacubitril-Valsartan 49-51Mg Oral Tablet

Clinical Study ID

NCT04153136
MGH2019P002355
  • Ages 40-70
  • All Genders

Study Summary

Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Antiretroviral therapy use for >12 months

  2. HIV Viral Load <200 copies/mL

  3. Left Ventricular Ejection Fraction>50%

  4. Demonstration of one or more criteria for myocardial dysfunction on cardiactransthoracic echocardiogram, relevant to the progression of heart failure withpreserved ejection fraction:

  • Left Atrial Volume Index > 28 mL/m2

  • Global Longitudinal Strain <18%

  • Left Ventricular Mass Index > 95g/m2 (female), 115 g/m2 (male)

Exclusion

Exclusion Criteria:

  1. Known history of congestive heart failure or valvular disease

  2. Recent cardiac event or stroke within 3 months

  3. Current medication use acting along the RAAS pathway (ACEi, ARB, MR blockade, directrenin inhibitor), potassium (K) supplementation or diuretic

  4. Angioedema to ACEi or ARB

  5. SBP<100 mmHg

  6. Medication suspected to have contraindication with active study drug

  7. Steroid use within last 3 months

  8. Uncontrolled diabetes requiring insulin and/or HbA1c > 7.5%

  9. Creatinine (Cr)>1.5 mg/dL and estimated GFR<60 mL/min/1.73m2

  10. K>5.5 mEq/L

  11. Hemoglobin <10.0 g/dL

  12. Known liver disease or ALT>3x upper limit normal

  13. Pregnant, actively seeking pregnancy or breastfeeding

  14. Estrogen, progestin derivative, or other sex steroid use within 3 months. Stablephysiologic testosterone replacement (> 3 months) is acceptable

  15. Current bacterial or other infection

  16. Active substance abuse

  17. Known reaction to gadolinium

Study Design

Total Participants: 39
Treatment Group(s): 2
Primary Treatment: Placebo oral tablet
Phase: 2
Study Start date:
September 11, 2020
Estimated Completion Date:
July 09, 2025

Study Description

This is a 6-month study enrolling persons with HIV with no known history of heart disease. Participants will be screened for early signs of heart failure using cardiac ultrasound (cardiac transthoracic echocardiography or cardiac TTE). Those participants who have early changes in the structure and function of the heart and may be at future risk for heart failure will be enrolled into the study. Additional imaging of the heart will occur using cardiac magnetic resonance imaging (cardiac MRI). Following baseline studies, participants will either receive a medication called sacubitril/valsartan or placebo for 6 months. Sacubitril/valsartan in an FDA approved medication currently being used for heart failure with reduced ejection fraction in the general population, and we are evaluating whether this medication could be useful to reduce HIV-related heart failure with preserved ejection fraction. Sacubitril/valsartan is an oral medication taken twice daily that may block aldosterone hormone and increase natriuretic peptide hormone. Overall, this study aims to investigate the effect of sacubitril/valsartan on measures of heart disease related to inflammation, structure and function of the heart muscle in HIV using cardiac TTE and cardiac MRI imaging as well as blood markers of heart failure and inflammation.

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston 4930956, Massachusetts 6254926 02114
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.